This observation suggested that BACH2 could be a promising independent and integrative predictor of outcome for CLL, although further validation in a larger cohort is essential to confirm BACH2 as a clinically significant prognosticator in CLL. Here, BACH2 is linked to B-cell chronic lymphocytic leukemia.